XETRA · MRK.DE
Merck KGaA
€150.30+€4.25 (+2.91%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
Loading market information…
NYSE · FMS · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Fresenius Medical Care AG & Co. KGaA’s quoted price sits in the lower half of its reported 52-week range, 14.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Fresenius Medical Care AG & Co. KGaA’s forward annual dividend is $0.86 per share, paid annual. The forward yield is 3.74% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Fresenius Medical Care AG & Co. KGaA’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of $0.65. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fresenius Medical Care AG & Co. KGaA’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 6, 2025 | $0.44+2.33% vs estimate | $5.35B+5.77% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | $0.48+17.07% vs estimate | $5.27B+13.1% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | $0.45+18.42% vs estimate | $5.22B-0.07% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
21 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $24.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€150.30+€4.25 (+2.91%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
€42.89+€0.30 (+0.7%)
Siemens Healthineers AG’s quoted price sits in the upper half of its reported 52-week range, 13.7% below the high.
€47.96+€1.93 (+4.19%)
Bayer Aktiengesellschaft’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
MX$953.08MX$0.00 (0.0%)
Bayer AG’s quoted price sits in the upper half of its reported 52-week range, 5.56% below the high.
€47.00+€0.67 (+1.44%)
Fresenius SE & Co. KGaA’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
$193.31+$9.38 (+5.1%)
DaVita Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.89% below the high.
$50.57-$0.28 (-0.54%)
Travere Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$0.74-$0.02 (-2.93%)
Akebia Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.01% below the high.
